- Home
- WDI vs NUVB Comparison
WDI vs NUVB Comparison
Compare WDI & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WDI
- NUVB
- Stock Information
- Founded
- WDI 2021
- NUVB 2018
- Country
- WDI United States
- NUVB United States
- Employees
- WDI N/A
- NUVB N/A
- Industry
- WDI Trusts Except Educational Religious and Charitable
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- WDI Finance
- NUVB Health Care
- Exchange
- WDI Nasdaq
- NUVB Nasdaq
- Market Cap
- WDI 753.0M
- NUVB 679.9M
- IPO Year
- WDI N/A
- NUVB N/A
- Fundamental
- Price
- WDI $14.69
- NUVB $1.96
- Analyst Decision
- WDI
- NUVB Strong Buy
- Analyst Count
- WDI 0
- NUVB 6
- Target Price
- WDI N/A
- NUVB $7.83
- AVG Volume (30 Days)
- WDI 192.6K
- NUVB 8.3M
- Earning Date
- WDI 01-01-0001
- NUVB 08-04-2025
- Dividend Yield
- WDI 11.80%
- NUVB N/A
- EPS Growth
- WDI N/A
- NUVB N/A
- EPS
- WDI 1.12
- NUVB N/A
- Revenue
- WDI N/A
- NUVB $10,957,000.00
- Revenue This Year
- WDI N/A
- NUVB $101.21
- Revenue Next Year
- WDI N/A
- NUVB $410.28
- P/E Ratio
- WDI $12.82
- NUVB N/A
- Revenue Growth
- WDI N/A
- NUVB N/A
- 52 Week Low
- WDI $12.16
- NUVB $1.54
- 52 Week High
- WDI $14.69
- NUVB $3.97
- Technical
- Relative Strength Index (RSI)
- WDI 51.81
- NUVB 45.69
- Support Level
- WDI $14.53
- NUVB $1.58
- Resistance Level
- WDI $14.94
- NUVB $2.14
- Average True Range (ATR)
- WDI 0.11
- NUVB 0.23
- MACD
- WDI -0.04
- NUVB -0.02
- Stochastic Oscillator
- WDI 39.02
- NUVB 33.91
About WDI Western Asset Diversified Income Fund of Beneficial Interest
Western Asset Diversified Income Fund is a newly-organized, diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).